Intraperitoneal administration of Corynebacterium parvum in patients with ascitic ovarian tumors resistant to chemotherapy: effects on cytotoxicity of tumor-associated macrophages and NK cells.
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy; D001201:Ascites / Q000628:therapy; D003602:Cytotoxicity, Immunologic; D005260:Female; D006106:Granulosa Cell Tumor / Q000276:immunology; D006801:Humans; D007274:Injections, Intraperitoneal; D007694:Killer Cells, Natural / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology; D008264:Macrophages / Q000276:immunology*; D009000:Monocytes / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*; D010166:Palliative Care; D011425:Propionibacterium acnes